about
Requirement for microtubule integrity in the SOCS1-mediated intracellular dynamics of HIV-1 GagDifferential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoformsAtg9a controls dsDNA-driven dynamic translocation of STING and the innate immune responseNegative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1.Characterization of RyDEN (C19orf66) as an Interferon-Stimulated Cellular Inhibitor against Dengue Virus ReplicationFollicular dendritic cells activate HIV-1 replication in monocytes/macrophages through a juxtacrine mechanism mediated by P-selectin glycoprotein ligand 1Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical applicationAntiviral protein Viperin promotes Toll-like receptor 7- and Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cellsHumanized NOD/SCID/IL2Rgamma(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesisNew approach for generation of neutralizing antibody against human T-cell leukaemia virus type-I (HTLV-I) using phage clones.Identification of the P-TEFb complex-interacting domain of Brd4 as an inhibitor of HIV-1 replication by functional cDNA library screening in MT-4 cells.TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation.Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides.Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds.A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity.Viability of infectious viral particles of HIV and BMCs in breast milk.Selective transmission of R5 HIV-1 over X4 HIV-1 at the dendritic cell-T cell infectious synapse is determined by the T cell activation state.Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion.CD4-independent human immunodeficiency virus infection involves participation of endocytosis and cathepsin B.Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production.Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS modelRegulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope.Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.Infection of XC cells by MLVs and Ebola virus is endosome-dependent but acidification-independent.Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells.Epstein-Barr virus induces erosive arthritis in humanized mice.Synthesis, structure-activity relationships, and mechanism of action of anti-HIV-1 lamellarin α 20-sulfate analogues.Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.Identification of RFPL3 protein as a novel E3 ubiquitin ligase modulating the integration activity of human immunodeficiency virus, type 1 preintegration complex using a microtiter plate-based assayLatency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with human myeloid cell nuclear differentiation antigen induced by interferon alpha.Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta.Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.A distinct role for Pin1 in the induction and maintenance of pluripotency.Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection.A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity
P50
Q24310319-AF50F8E4-C65F-46B8-9147-ED0666BAAB12Q24337486-96C76B63-192A-4D5F-A5BB-160AFBACF3DDQ24643548-59B5318E-8DB1-4F47-821F-782618AED350Q27863922-AD32A3A1-CF82-48C1-9B2B-788234B31CC2Q28116367-785B8405-CA0A-4D53-B039-742BC61D99E5Q28249329-7580AF7E-135B-43F7-A473-3560BDCC0B4BQ28486916-63BE25E5-DB43-4BB9-A12C-003AF97281DAQ28594284-7A09DF82-859A-423A-8CF7-8BCFA54AF4CEQ28756080-27FE940E-25A0-4B3B-8173-8CA159578B84Q30803056-4C414928-1070-41D7-96FB-314173C4E904Q30852789-737B1F9D-5387-42ED-A30A-5AB517F9FC33Q31148506-17265E0F-AF46-44AE-A3ED-74577CE19E25Q31164451-C8FA9688-FFB7-43A1-A3ED-EA13D2206D6EQ33200970-257F840F-CFFD-4708-8ABF-22E3153E9354Q33228479-0C909634-911A-4E9D-A4D0-62ED1AD12358Q33228536-9EDF610F-8D52-451F-BB41-F019FDDD5EB5Q33285801-ABE96135-8324-4D25-9C86-DDFCA8000BD1Q33404066-4C51F6BD-1CE2-403A-B668-2BD8577F7DADQ33717525-7FAB189B-6793-4D80-9D1A-55107998355CQ33724164-123A3C68-F45F-40B9-B1D8-820060A5C059Q33889483-9ADF9478-77CC-470D-BAFA-192DFAC6A87CQ33910600-36F3A496-0771-47DC-B137-C1A2A39D94A7Q33912052-0947B0C1-9CEE-498F-B4DC-62F7896A8C3EQ34002425-6E1ED9BB-63DA-49B2-9E54-F5069CB6EC78Q34045678-E78B7ACE-4FFB-4607-9B77-6474F2C35C41Q34056123-6A362697-643E-43ED-B546-4D7B74DFC9CAQ34058148-64F554D8-D5AE-4C97-BD46-89B2058F3C37Q34058760-3C147A1C-3DDA-499F-85EE-7AC1B658D0C3Q34071105-5D25E8B9-598E-4085-8375-ECA1919EA17EQ34227778-077483F1-00E0-42D2-B2F8-1DB250031E77Q34249142-A673EF64-5B65-456A-A60F-1FFB71A36AD3Q34276926-C33538F4-CA01-4323-B78A-97732D832204Q34331980-C6F196CA-38B7-47EE-A319-BB24A709B0FDQ34483726-61205B6C-326B-451A-A3D5-9CCACAF06AF0Q34648342-8BD8C46C-3BC2-4971-9226-584AEB0116C3Q34648429-AF175CA9-F084-4CAF-9E72-1A40D08BA08CQ34719741-035F4E80-5A77-4B09-B8AC-536DD7BF320DQ34774226-A5E4818F-410D-4A43-8BAE-FA965755AAA8Q34808530-34AD0CA7-D845-4670-9671-29824272260FQ34955359-9FF53764-3D88-481C-89C3-35ECD2B8B59C
P50
name
Naoki Yamamoto
@en
type
label
Naoki Yamamoto
@en
prefLabel
Naoki Yamamoto
@en